Supporting Information

Transforming an Azaarene into the Spine of Fused Bicyclics via Cycloaddition-Induced Scaffold Hopping of 5-Hydroxypyrazoles

You Zhou,¹ Shuang-Gui Lei,¹ Baihetiguli Abudureheman,¹ Li-Sheng Wang,¹ Zhi-Cheng Yu,¹ Jia-Chen Xiang,^{2,*} and An-Xin Wu^{1, 3,*}

Affiliations:

1. National Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, P.R. China.

2. School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, P.R. China.

3. State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, 730000 P. R. China.

Correspondence and requests for materials should be addressed to A-X. W. (email: chwuax@mail.ccnu.edu.cn) and J-C. X (email: xiangjiachen@seu.edu.cn)

| Table | page | |
|-------|---|----------|
| 1. | General | S2 |
| 2. | Screening of the reaction conditions | S3 |
| 3. | Synthetic operation method of target product and substrate | S4-S11 |
| 4. | Mechanistic studies | S12-S14 |
| 5. | Characterization data for compounds | S15-S52 |
| 6. | Crystallographic data and molecular structure of 4e and 7b | |
| 7. | ¹ H, ¹³ C, ¹⁹ F and ³¹ P NMR spectra of compounds | S57-S149 |
| 8. | References | S150 |

1. General

All substrates and reagents were commercially available and used without further purification. TLC analysis was performed using pre-coated glass plates. Column chromatography was performed using silica gel (200–300 mesh). ¹H, ¹³C, ¹⁹F and ³¹P spectra were recorded in CDCl₃ or DMSO-d₆ on Bruker 400 MHz NMR (AVANCE III HD 400) spectrometers and chemical shifts of ¹H NMR are reported in ppm, relative to the internal standard of tetramethylsilane (CDCl₃, $\delta_{(TMS)} = 0.00$ ppm; DMSO- d_6 , $\delta = 2.50$ ppm). Chemical shifts of ¹³C NMR were reported in ppm with the solvent as the internal standard (CDCl₃, $\delta = 77.0$ ppm; DMSO- d_{δ} , $\delta = 39.5$ ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constants (Hz) and integration. ¹³C spectra were recorded in CDCl₃ on 100 MHz NMR spectrometers and resonances (δ) are given in ppm. ¹⁹F spectra were recorded in CDCl₃ on 376 MHz NMR spectrometers and resonances (δ) are given in ppm. ³¹P spectra were recorded in CDCl₃ on 162 MHz NMR spectrometers and resonances (δ) are given in ppm. The high resolution mass spectrometers were obtained on an Agilent LC1290-TOF 6224 or German Thermo Fisher Q Exactive equipped with an electrospray source. The X-ray crystal-structure determinations of 4e and 7b were obtained on a Bruker APEX DUO CCD The crystals were mounted on a glass fiber for diffraction experiments. Intensity data were collected on a Bruker SMART APEX CCD diffractometer with Mo Ka radiation (0.71073 Å) at room temperature. Melting points were determined using XT-4 apparatus and not corrected.

2. Screening of the reaction conditions

Supplementary Table 1: Screening of the reaction conditions^a



| Entry | I ₂ (equiv.) | Additives (equiv.) | Temp (℃) | Yield $(\%)^b$ |
|-------|-------------------------|-----------------------------|----------|----------------|
| 1 | 1.0 | - | 100 | 47 |
| 2 | 1.0 | <i>t</i> -BuCOOH (1.0) | 100 | 45 |
| 3 | 1.0 | CF ₃ COOH (1.0) | 100 | 38 |
| 4 | 1.0 | 50% HI (1.0) | 100 | 46 |
| 5 | 1.0 | TfOH (1.0) | 100 | 50 |
| 6 | 1.0 | Tf ₂ NH (1.0) | 100 | 48 |
| 7 | 1.0 | TsOH (1.0) | 100 | 47 |
| 8 | 1.0 | FeCl ₃ (1.0) | 100 | 45 |
| 9 | 1.0 | CuCl ₂ (1.0) | 100 | 39 |
| 10 | 1.0 | Cu(OTf) ₂ (1.0) | 100 | 63 |
| 11 | 1.0 | ZnCl ₂ (1.0) | 100 | 58 |
| 12 | 1.0 | NiCl ₂ (1.0) | 100 | 60 |
| 13 | 1.0 | $K_2S_2O_8$ (1.0) | 100 | 19 |
| 14 | 1.0 | PhI(OAc) ₂ (1.0) | 100 | 12 |
| 15 | 1.0 | 70% TBHP (1.0) | 100 | 43 |
| 16 | 1.0 | DTBP (1.0) | 100 | 72 |
| 17 | 1.0 | AIBN (1.0) | 100 | 70 |
| 18 | 1.0 | DCP (1.0) | 100 | 67 |
| 19 | 0.5 | DTBP (1.0) | 100 | 60 |
| 20 | 1.5 | DTBP (1.0) | 100 | 63 |
| 21 | 2.0 | DTBP (1.0) | 100 | 57 |
| 22 | 1.0 | DTBP (2.0) | 100 | 75 |
| 23 | 1.0 | DTBP (3.0) | 100 | 70 |
| 24 | 1.0 | DTBP (2.0) | 80 | 59 |
| 25 | 1.0 | DTBP (2.0) | 90 | 68 |
| 26 | 1.0 | DTBP (2.0) | 110 | 72 |
| 27 | 1.0 | DTBP (2.0) | 120 | 62 |

^{*a*}Reaction conditions: **1a** (1.2 mmol), **2a** (1.0 mmol), **3a** (1.0 mmol), I_2 (x mmol) and Additives (x mmol) at T $^{\circ}$ C for 4 h under air. ^{*b*}Isolated yields.

3. Synthetic operation method of target product and substrate



Synthesis of Acetophenone derived from active molecules (1aa-1af)¹⁻²

4-Acetylbenzoic acid (**11a**, 10 mmol, 1642 mg), (-)-menthol (10 mmol, 1563 mg), [or (+)-borneol (10 mmol, 1543 mg), 1-adamantanamine (10 mmol, 1513 mg)] and 4dimethylaminopyridine (DMAP, 3 mmol, 366 mg) were added to a 100 mL round-bottomed flask, then 50 mL of dichloromethane was added and mixed well to form a solution, and add the condensation reagent *N*, *N*-diisopropylcarbodiimide (DIC, 15 mmol, 1890 mg) while stirring the solution. Keep the mixture stirred at room temperature for 6 hours using a magnetic stirrer to complete the reaction. At the end of the reaction, the organic phase was extracted and partitioned with ethyl acetate and NaCl aqueous solution, and the crude product mixture was obtained after rotary evaporation under reduced pressure. Finally, the pure target product was obtained by column chromatography separation with a yield higher than 90%.



Carboxylic acid (10 mmol), 4-hydroxyacetophenone(**11b**, 10 mmol, 1362 mg), [or 4aminoacetophenone (**11c**, 10 mmol, 1352 mg)] and 4-dimethylaminopyridine (DMAP, 3 mmol, 366 mg) were added to a 100 mL round-bottomed flask, then 50 mL of dichloromethane was added and mixed well to form a solution, and add the condensation reagent N, Ndiisopropylcarbodiimide (DIC, 15 mmol, 1890 mg) while stirring the solution. Keep the mixture stirred at room temperature for 6 hours using a magnetic stirrer to complete the reaction. At the end of the reaction, the organic phase was extracted and partitioned with ethyl acetate and NaCl aqueous solution, and the crude product mixture was obtained after rotary evaporation under reduced pressure. Finally, the pure target product was obtained by column chromatography separation with a yield higher than 90%.

Synthesis method of 5-aminopyrazole (2)³⁻⁵



General procedure for 3-methyl-5-aminopyrazole: The substituted hydrazine hydrochloride (**8**, 5.0 mmol) was placed in a 38 mL glass reaction tube, and then K_2CO_3 (5.0 mmol, 690 mg) was added separately, followed by 15 mL of DMSO and 2 mL of H₂O as solvent, so that the mixture was stirred well on the reaction pot, and then 3-aminocrotononitrile (**9**, 6.0 mmol, 492 mg) was added, and finally the reaction was carried out at 110 °C for 5h. The target product in the reaction solution could be detected by TLC, and after the reaction was completed, the fraction was extracted with NaCl aqueous solution and ethyl acetate, and the combined

organic phases were spun dry, and finally the pure target product was obtained by column chromatography (eluent polarity, EA:PE=5:1-3:1, yield above 90%).



Synthesis method of 5-hydroxypyrazole (3)⁶⁻⁷



General procedure for 5-hydroxypyrazole: Add methyl 3-methoxyacrylate (10 mmol, 1160 mg) and phenylhydrazine (10 mmol, 1080 mg) [or benzylhydrazine (10 mmol, 1220 mg)] to a 38mL glass tube, and add 20mL n-propanol as the reaction solvent, and finally the reaction was carried out at 120 $^{\circ}$ C for 8h. The target product in the reaction solution could be detected by TLC, and after the reaction was completed, the fraction was extracted with NaCl aqueous solution and ethyl acetate, and the combined organic phases were spun dry, and finally the pure target product was obtained by column chromatography (eluent polarity, EA, yield above 60%).

NMR spectra of 3-hydroxypyrazole in DMSO-d₆



Supplementary Figure 1. ¹H NMR and ¹³C NMR spectra of 3a.



Supplementary Figure 2. ¹H NMR and ¹³C NMR spectra of 3f.





General procedure for the synthesis of 4-7 (4a or 6b as example)



1.0 mmol scale (4a): The reactions did not require the protection of inert gases. In a 35 mL sealed tube were added acetophenone (**1a**) (144 mg, 1.2 mmol), iodine (254 mg, 1.0 mmol) and dimethyl sulfoxide (5 mL) and the resulting mixture was stirred at 100 °C (heating block), the reaction tube was removed after about 1 hour. Then additional **2a** (173 mg, 1.0 mmol), **3a** (98 mg, 1.0 mmol) and DTBP (292 mg, 2.0 mmol) were added at room temperature, followed by reaction at 100 °C for 4 hours until substrate conversion was almost complete by TLC analysis. After the reaction stopped and cooled at room temperature, the reaction mixture was quenched with saturated Na₂S₂O₃ solution (50 mL) and NaCl solution (200 mL). The mixture was then extracted with EtOAc (150mL × 2), and the organic layers were separated and merged. The mixture was dried with anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc = 12:1) to afford the product **4a** (275 mg, 75% yield).



8.0 mmol scale (6b): The reactions did not require the protection of inert gases. In a 100 mL round flask were added *p*-methylacetophenone (**1b**) (1.29 g, 9.6 mmol), iodine (2.03 g, 8 mmol) and dimethyl sulfoxide (30 mL) and the resulting mixture was stirred in oil bath heating at 100 °C, the round flask was removed after about 1.5 hour. Then additional **2k** (0.89 g, 8.0 mmol), **3a** (0.78 g, 8.0 mmol) and DTBP (2.34 g, 16 mmol) were added at room temperature, followed by reaction at 100 °C for 6 hours until substrate conversion was almost complete by TLC analysis. After the reaction stopped and cooled at room temperature, the reaction mixture was quenched with saturated Na₂S₂O₃ solution (150 mL) and NaCl solution (450 mL). The mixture was then extracted with EtOAc (300mL × 3), and the organic layers were separated and merged. The mixture was dried with anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc = 8:1) to afford the product **6b** (1.81 g, 71% yield).

Post-modification methods of 4n molecules



Product of *para*-bromine **4n** (134 mg, 0.3 mmol), phenylacetylene (46 mg, 0.45 mmol), Pd(PPh₃)₂Cl₂(9.8 mg, 0.015 mmol), CuI (5.7 mg, 0.03 mmol), NEt₃ (2 mL) and THF (2 mL). The vial was then purged with argon and sealed, and heated under an argon atmosphere 80 °C for 10 h. Until the disappearance of starting material was observed, as monitored by thin layer chromatography. After cooling to room temperature, the reaction solution was mixed with NaCl solution 300 mL), and then the mixture was extracted twice with EtOAc (100 mL x 2). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated using a rotary evaporator under reduced pressure. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc = 12:1) to afford the product **8** (120 mg, 86% yield).⁸



A mixture of **4n** (134 mg, 0.3 mmol), di-*p*-tolylphosphine oxide (104 mg, 0.45 mmol), palladium (II) acetate (4.5 mg, 0.02 mmol), (*t*-Bu₃)PHBF₄ (12.0 mg, 0.04 mmol), Cs₂CO₃ (196 mg, 0.6 mmol) and dry-toluene (4 mL), and heated under an argon atmosphere 110 °C for 10 h. After cooling to room temperature, the reaction solution was mixed with NaCl solution (300 mL), and then the mixture was extracted twice with EtOAc (100 mL x 2). The organic layer was separated and washed with brine, dried over anhydrous Na₂SO₄ and evaporated to dryness under reduced pressure. The crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc = 2:1) to afford the product **9** (149 mg, 84% yield).^{9, 10}

4. Mechanistic studies



HRMS experiments were conducted to study the mechanisms. The reactions did not require the protection of inert gases. In a 35 mL sealed tube were added deuterated acetophenone- d_3 (**1a-D**) (148 mg, 1.2 mmol), iodine (254 mg, 1.0 mmol) and dimethyl sulfoxide (5 mL) and the resulting mixture was stirred at 100 °C (heating block), the reaction tube was removed after about 1 hour. Then additional **2a** (173 mg, 1.0 mmol), **3a** (98 mg, 1.0 mmol) and DTBP (292 mg, 2.0 mmol) were added at room temperature, followed by reaction at 100 °C for 40 mins, then wait for the reaction to cool to room temperature. Take 0.5 mL of reaction solution and dilute it with 4 mL of EtOAc. Then 1.5 mL of the extraction solution was added into the test bottle, the samples were immediately monitored by German Thermo Fisher Q Exactive high resolution mass spectrometers.



Supplementary Figure 4. High-resolution mass spectrometry of intermediate 1ab-D.



Supplementary Figure 5. High-resolution mass spectrometry of intermediate A.



Supplementary Figure 6. High-resolution mass spectrometry of intermediate B.



Supplementary Figure S7. High-resolution mass spectrometry of intermediate C.



Supplementary Figure 8. High-resolution mass spectrometry of intermediate D.



Supplementary Figure 9. High-resolution mass spectrometry of product 4a.

6. Characterization data for compounds



1,7-dimethyl-3,9-diphenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (4a):

Yield 75%; 275 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 235–237 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.70 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.60-7.50 (m, 7H), 7.37 (t, *J* = 7.2 Hz, 1H), 3.95 (s, 3H), 1.59 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.4, 150.1, 144.3, 143.7, 138.3, 138.2, 130.7, 129.6, 129.3, 129.12, 129.09, 127.0, 122.4, 117.7, 107.6, 39.6, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₈N₅O⁺: 368.1506; found: 368.1505.



1,7-dimethyl-3-phenyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (4b):

Yield 74%; 281 mg; white solid; column chromatography, silica gel (PE:EA, 12:1); mp 211–213 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.54 (t, *J* = 7.6 Hz, 2H), 7.46 (d, *J* = 7.6 Hz, 2H), 7.38-7.33 (m, 3H), 3.94 (s, 3H), 2.47 (s, 3H), 1.63 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 152.4, 150.1, 144.4, 143.8, 139.7, 138.3, 135.3, 130.8, 129.7, 129.13, 129.10, 126.9, 122.4, 117.8, 107.7, 39.6, 21.4, 15.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₀N₅O⁺: 382.1662; found: 382.1662.



9-(4-(*tert*-butyl)phenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4c):

Yield 77%; 325 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 223–225 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.68 (s, 1H), 8.13 (d, *J* = 8.0 Hz, 2H), 7.56-7.48 (m, 6H), 7.36 (t, *J* = 7.2 Hz, 1H), 3.94 (s, 3H), 1.57 (s, 3H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 153.1, 152.4, 150.0, 144.4, 143.8, 138.3, 135.2, 130.9, 129.1, 128.9, 126.9, 126.1, 122.3, 117.7, 107.8, 39.6, 34.8, 31.2, 14.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₆H₂₆N₅O⁺: 424.2132; found: 424.2130.



9-(4-cyclohexylphenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4d):

Yield 72%; 323 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 204–206 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.67 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.47 (d, *J* = 7.6 Hz, 2H), 7.36 (d, *J* = 7.6 Hz, 3H), 3.93 (s, 3H), 2.64-2.57 (m, 1H), 1.94-1.87 (m, 4H), 1.78 (d, *J* = 12.4 Hz, 1H), 1.56 (s, 3H), 1.52-1.38 (m, 4H), 1.32-1.25 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.3, 150.0, 149.9, 144.5, 143.8, 138.3, 135.5, 130.8, 129.1, 129.0, 127.6, 126.8, 122.3, 117.7, 107.7, 44.4, 39.6, 34.3, 26.7, 26.0, 14.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₈H₂₈N₅O⁺: 450.2288; found: 450.2288.



9-(4-methoxyphenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4e):

Yield 70%; 278 mg; light yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 183–185 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 8.13 (d, *J* = 7.2 Hz, 2H), 7.58-7.47 (m, 4H), 7.37 (t, *J* = 6.4 Hz, 1H), 7.06 (d, *J* = 7.6 Hz, 2H), 3.94 (s, 3H), 3.90 (s, 3H), 1.70 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.7, 158.4, 152.4, 150.1, 144.2, 143.7, 138.3, 130.8,

130.7, 130.5, 129.1, 126.9, 122.4, 117.8, 114.5, 107.8, 55.5, 39.6, 15.5. HRMS (ESI-TOF): m/z $[M+H]^+$ calcd for $C_{23}H_{20}N_5O_2^+$: 398.1612; found: 398.1612.



9-(2-methoxyphenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4f):

Yield 72%; 285 mg; light yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 220–222 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.71 (s, 1H), 8.13 (d, *J* = 8.0 Hz, 2H), 7.56-7.48 (m, 4H), 7.34 (t, *J* = 7.2 Hz, 1H), 7.15 (t, *J* = 7.2 Hz, 1H), 7.02 (d, *J* = 8.4 Hz, 1H), 3.94 (s, 3H), 3.64 (s, 3H), 1.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 158.5, 152.3, 150.2, 143.5, 141.9, 138.4, 132.2, 131.5, 131.4, 129.0, 127.2, 126.8, 122.4, 121.0, 117.2, 111.2, 107.6, 55.5, 39.6, 15.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₀N₅O₂⁺: 398.1612; found: 398.1611.



9-(benzo[d][1,3]dioxol-5-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (4g):

Yield 70%; 287 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 246–248 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.65 (s, 1H), 7.88 (d, *J* = 8.0 Hz, 2H), 7.55 (t, *J* = 7.6 Hz, 2H), 7.44 (t, *J* = 7.2 Hz, 1H), 7.10 (s, 1H), 6.98 (dd, *J* = 19.6 Hz, 8.0 Hz, 2H), 6.13 (s, 1H), 6.07 (s, 1H), 3.99 (s, 3H), 1.86 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.2, 151.8, 150.4, 149.2, 148.5, 145.6, 144.4, 136.9, 131.5, 131.0, 129.3, 128.3, 123.7, 123.5, 117.6, 109.5, 108.9, 107.5, 101.8, 40.3, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₈N₅O₃⁺: 412.1404; found: 412.1401.



1,7-dimethyl-3-phenyl-9-(4-((trimethylsilyl)methoxy)phenyl)-3,7-dihydro-6H-pyrazolo [4',3':5,6]pyrido[3,4-d]pyridazin-6-one (4h):

Yield 74%; 347 mg; gray solid; column chromatography, silica gel (PE:EA, 10:1); mp 133–135 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.52 (t, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.09 (d, *J* = 8.8 Hz, 2H), 3.92 (s, 3H), 3.67 (s, 2H), 1.70 (s, 3H), 0.19 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 162.7, 158.4, 152.4, 150.0, 144.3, 143.8, 138.3, 130.8, 130.3, 130.2, 129.0, 126.8, 122.3, 117.7, 114.7, 107.8, 61.5, 39.5, 15.6, -3.14. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₆H₂₈N₅O₂Si⁺: 470.2007; found: 470.2006.



1,7-dimethyl-9-(4-(methylthio)phenyl)-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (4i):

Yield 73%; 301 mg; light yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 210–212 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.67 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.53 (t, *J* = 8.0 Hz, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.40-7.34 (m, 3H), 3.93 (s, 3H), 2.55 (s, 3H), 1.70 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.4, 150.0, 143.8, 143.5, 141.0, 138.3, 134.6, 130.6, 129.5, 129.1, 126.9, 126.4, 122.3, 117.7, 107.6, 39.6, 15.7, 15.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₀N₅OS⁺: 414.1383; found: 414.1381.



9-(4-fluorophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (4j):

Yield 71%; 273 mg; white solid; column chromatography, silica gel (PE:EA, 12:1); mp 193–195 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 8.12 (d, *J* = 7.6 Hz, 2H), 7.65-7.47 (m, 4H), 7.38 (t, *J* = 7.2 Hz, 1H), 7.28-7.19 (m, 2H), 3.94 (s, 3H), 1.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.5 (d, *J* = 249.0 Hz, ¹*J*_{CF}), 158.4, 152.4, 150.1, 143.3, 143.2, 138.3, 134.4, 131.2 (d, *J* = 9.0 Hz, ³*J*_{CF}), 130.5, 129.1, 127.0, 122.4, 117.7, 116.3 (d, *J* = 22.0 Hz, ²*J*_{CF}), 107.5, 39.6, 15.5. ¹⁹F NMR (376 MHz, CDCl₃) δ -110.62. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₇N₅OF⁺: 386.1412; found: 386.1415.



9-(3,5-difluorophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4k):

Yield 72%; 290 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 257–259 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.70 (s, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.47 (t, J = 7.2 Hz, 1H), 7.17 (d, J = 4.8 Hz, 2H), 7.07 (t, J = 8.4 Hz, 1H), 4.04 (s, 3H), 1.83 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 163.4 (dd, ¹ $J_{CF} = 250.0$ Hz, ³ $J_{CF} = 12.0$ Hz), 159.2, 151.7, 150.7, 143.9, 143.4, 140.1 (t, ³ $J_{CF} = 9.0$ Hz), 136.7, 130.8, 129.4, 128.6, 123.9, 117.6, 112.8 (dd, ² $J_{CF} = 19.0$ Hz, ⁴ $J_{CF} = 8.0$ Hz), 107.0, 105.7 (t, ² $J_{CF} = 25.0$ Hz), 40.6, 15.2. ¹⁹F NMR (376 MHz, CDCl₃, CF₃COOD) δ -107.45. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₆N₅OF₂⁺: 404.1317; found: 404.1313.



9-(2-chlorophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (4l):

Yield 69%; 277 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 244–246 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.72 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.63-7.43 (m, 6H), 7.36 (t, *J* = 7.6 Hz, 1H), 3.95 (s, 3H), 1.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 152.3, 150.3, 143.3, 141.7, 138.3, 137.0, 135.0, 132.2, 131.3, 130.1, 129.1, 127.3, 127.0, 122.5, 117.1, 107.1, 39.7, 14.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₇N₅OCl⁺: 402.1116; found: 402.1114.



9-(2,4-dichlorophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4m):

Yield 72%; 313 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 178–180 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 8.11 (d, *J* = 7.6 Hz, 2H), 7.60-7.45 (m, 5H), 7.36 (t, *J* = 7.2 Hz, 1H), 3.93 (s, 3H), 1.73 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.3, 150.2, 142.8, 140.6, 138.2, 136.7, 135.9, 135.6, 132.9, 131.0, 129.8, 129.0, 127.7, 127.0, 122.5, 117.0, 106.9, 39.7, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₆N₅OCl₂⁺: 436.0726; found: 436.0729.



9-(4-bromophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (4n):

Yield 69%; 307 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 222–224 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.11 (d, *J* = 7.6 Hz, 2H), 7.67 (d, *J* = 7.6 Hz, 2H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.45 (d, *J* = 7.6 Hz, 2H), 7.35 (t, *J* = 7.2 Hz, 1H), 3.92 (s, 3H), 1.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.3, 150.0, 143.2, 143.0, 138.2, 137.0, 132.2, 130.8, 130.1, 129.0, 126.9, 123.9, 122.2, 117.6, 107.3, 39.6, 15.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₇N₅OBr⁺: 446.0611; found: 446.0613.



9-(3-bromophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (40):

Yield 65%; 289 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 229–231 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 8.12 (d, *J* = 7.2 Hz, 2H), 7.75 (s, 1H), 7.69 (d, *J* = 7.2 Hz, 1H), 7.57-7.48 (m, 3H), 7.43-7.35 (m, 2H), 3.94 (s, 3H), 1.68 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.3, 150.1, 143.2, 142.6, 140.0, 138.2, 132.7, 132.2, 130.6, 130.2, 129.1, 127.9, 127.0, 123.1, 122.4, 117.6, 107.3, 39.7, 15.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₇N₅OBr⁺: 446.0611; found: 446.0611.



9-(4-iodophenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (4p):

Yield 73%; 359 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 239–241 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.52 (t, *J* = 8.0 Hz, 2H), 7.37-7.30 (m, 3H), 3.92 (s, 3H), 1.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.3, 150.0, 143.2, 143.1, 138.21, 138.17, 137.6, 130.9, 130.1, 129.0, 126.9, 122.3, 117.6, 107.4, 95.6, 39.6, 15.8. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₇N₅OI⁺: 494.0472; found: 494.0468.



1,7-dimethyl-3-phenyl-9-(4-(trifluoromethyl)phenyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (4q):

Yield 70%; 304 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 188–190 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.81 (d, *J* = 8.0 Hz, 2H), 7.72 (d, *J* = 8.0 Hz, 2H), 7.52 (t, *J* = 8.0 Hz, 2H), 7.36 (t, *J* = 7.6 Hz, 1H), 3.94 (s, 3H), 1.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.3, 150.0, 143.0, 142.6, 141.6, 138.2, 131.7 (q, *J* = 32.0 Hz, ²*J*_{CF}), 130.0, 129.7, 129.1, 127.0, 126.0 (q, *J* = 3.0 Hz, ⁴*J*_{CF}), 123.7 (q, *J* = 271.0 Hz, ¹*J*_{CF}), 122.3, 117.6, 107.2, 39.7, 15.6. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.66. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₇N₅OF₃⁺: 436.1380; found: 436.1378.



1,7-dimethyl-3-phenyl-9-(3-(trifluoromethoxy)phenyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (4r):

Yield 71%; 320 mg; light yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 190–192 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.57 (t, *J* = 8.0 Hz, 1H), 7.54-7.45 (m, 4H), 7.42 (d, *J* = 8.0 Hz, 1H), 7.33 (t, *J* = 7.2 Hz, 1H), 3.91 (s, 3H), 1.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.1, 152.2, 149.8, 149.59, 149.57, 143.0, 142.3, 140.0, 138.2, 130.5, 130.0, 128.9, 127.8, 126.8, 122.04, 121.96, 121.9, 120.3 (q, *J* = 257.0 Hz, ¹*J*_{CF}), 117.5, 107.2, 39.6, 15.2. ¹⁹F NMR (376 MHz, CDCl₃) δ -57.65. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₇N₅O₂F₃⁺: 452.1329; found: 452.1326.



methyl 4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-9-yl)benzoate (4s):

Yield 67%; 284 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 228–230 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.20 (d, *J* = 7.6 Hz, 2H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.66 (d, *J* = 7.6 Hz, 2H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.34 (t, *J* = 7.2 Hz, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 1.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 166.2, 158.2, 152.2, 149.9, 143.1, 143.0, 142.3, 138.2, 130.9, 130.2, 130.0, 129.3, 129.0, 126.8, 122.1, 117.5, 107.3, 52.3, 39.6, 15.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₂₀N₅O₃⁺: 426.1561; found: 426.1560.



4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-9-yl)benzonitrile (4t):

Yield 66%; 258 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 275–277 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.72 (s, 1H), 7.92 (d, *J* = 7.6 Hz, 2H), 7.85 (d, *J* = 7.6 Hz, 2H), 7.78 (d, *J* = 7.6 Hz, 2H), 7.57 (t, *J* = 7.2 Hz, 2H), 7.52-7.45 (m, 1H), 4.05 (s, 3H), 1.69 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.2, 151.6, 150.8, 143.8, 143.6, 141.9, 136.6, 133.1, 130.7, 130.1, 129.5, 128.8, 124.1, 117.7, 117.4, 113.4, 107.0, 40.6, 15.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₇N₆O₃⁺: 393.1458; found: 393.1457.



1,7-dimethyl-9-(4-nitrophenyl)-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (4u):

Yield 70%; 288 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 262–264 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.82 (s, 1H), 8.48 (d, *J* = 8.4 Hz, 2H), 7.89 (d, *J* = 8.4 Hz, 2H), 7.68-7.58 (m, 5H), 4.10 (s, 3H), 1.76 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.4, 151.4, 150.8, 148.8, 144.5, 143.9, 143.3, 135.2, 131.9, 130.6, 130.4, 129.9, 125.5, 124.7, 118.2, 107.5, 40.9, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₇N₆O₃⁺: 413.1357; found: 413.1355.



3-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-9-yl)benzonitrile (4v):

Yield 68%; 266 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 253–255 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.70 (s, 1H), 7.98 (s, 1H), 7.90 (t, *J* = 7.2 Hz, 3H), 7.85 (d, *J* = 7.6 Hz, 1H), 7.73 (t, *J* = 7.6 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 2H), 7.46 (t, *J* = 7.2 Hz, 1H), 4.03 (s, 3H), 1.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.1, 151.8, 150.5, 143.3, 138.8, 136.9, 133.8, 133.5, 132.7, 130.6, 130.2, 129.4, 128.4, 123.6, 117.5, 117.4, 113.3, 106.9, 40.5, 15.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₇N₆O₃⁺: 393.1458; found: 393.1455.



1,7-dimethyl-9-(3-nitrophenyl)-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (4w):

Yield 67%; 276 mg; light yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 249–251 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 8.51 (s, 1H), 8.41 (d, *J* = 8.0 Hz, 1H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.89 (d, *J* = 7.6 Hz, 1H), 7.74 (t, *J* = 8.0 Hz, 1H), 7.53 (t, *J* = 8.0 Hz, 2H), 7.37 (t, *J* = 7.2 Hz, 1H), 3.95 (s, 3H), 1.61 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.3, 150.1, 148.6, 142.5, 141.5, 139.8, 138.2, 135.2, 130.1, 129.8, 129.1, 127.1, 124.3, 124.2,

122.3, 117.6, 107.0, 39.7, 16.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for $C_{22}H_{17}N_6O_3^+$: 413.1357; found: 413.1359.



1,7-dimethyl-9-(4-(methylsulfonyl)phenyl)-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (4x):

Yield 73%; 324 mg; yellow solid; column chromatography, silica gel (PE:EA, 3:1); mp 265–267 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.78 (s, 1H), 8.20 (d, *J* = 8.0 Hz, 2H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.72 (d, *J* = 7.6 Hz, 2H), 7.62-7.53 (m, 3H), 4.08 (s, 3H), 3.26 (s, 3H), 1.68 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.3, 151.24, 151.21, 144.0, 143.9, 142.9, 141.1, 135.8, 131.4, 130.7, 129.7, 128.4, 125.0, 118.0, 107.2, 44.4, 40.8, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₀N₅O₃S⁺: 446.1281; found: 446.1275.



1,7-dimethyl-9-(naphthalen-1-yl)-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4y):

Yield 68%; 283 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 251–253 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.82 (s, 1H), 8.11 (dd, *J* = 6.8 Hz, 2.8 Hz, 1H), 8.00 (d, *J* = 8.4 Hz, 1H), 7.80 (d, *J* = 8.0 Hz, 2H), 7.67-7.61 (m, 2H), 7.60-7.50 (m, 4H), 7.48-7.41 (m, 2H), 4.06 (s, 3H), 1.06 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.4, 151.8, 151.0, 145.0, 144.4, 136.7, 134.3, 133.7, 133.1, 132.7, 130.8, 129.3, 128.8, 128.6, 128.5, 127.7, 126.9, 125.4, 124.4, 124.1, 117.3, 107.0, 40.6, 14.3. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₆H₂₀N₅O⁺: 418.1662; found: 418.1661.



1,7-dimethyl-9-(naphthalen-2-yl)-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (4z):

Yield 72%; 300 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 191–193 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.73 (s, 1H), 8.13 (d, *J* = 8.0 Hz, 2H), 8.02 (d, *J* = 11.6 Hz, 2H), 7.95 (d, *J* = 7.2 Hz, 1H), 7.88 (d, *J* = 7.2 Hz, 1H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.61-7.50 (m, 4H), 7.37 (t, *J* = 7.2 Hz, 1H), 3.98 (s, 3H), 1.44 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 152.4, 150.2, 144.3, 143.6, 138.3, 135.4, 133.4, 133.1, 130.7, 129.1, 129.0, 128.8, 128.3, 127.9, 127.2, 127.00, 126.99, 126.4, 122.4, 117.8, 107.7, 39.7, 15.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₆H₂₀N₅O⁺: 418.1662; found: 418.1660.



9-(9H-fluoren-2-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5a):

Yield 70%; 318 mg; white solid; column chromatography, silica gel (PE:EA, 12:1); mp 242–244 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.70 (s, 1H), 8.13 (d, *J* = 8.0 Hz, 2H), 7.92 (d, *J* = 8.0 Hz, 1H), 7.87 (d, *J* = 7.6 Hz, 1H), 7.76 (s, 1H), 7.61-7.51 (m, 4H), 7.44 (t, *J* = 7.2 Hz, 1H), 7.37 (dd, *J* = 13.6 Hz, 6.8 Hz, 2H), 4.00 (s, 2H), 3.96 (s, 3H), 1.61 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.4, 150.1, 144.6, 144.0, 143.7, 143.6, 143.0, 140.7, 138.3, 136.4, 130.8, 129.1, 128.1, 127.5, 127.0, 126.9, 125.8, 125.2, 122.4, 120.40, 120.38, 117.8, 107.8, 39.6, 36.9, 15.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₉H₂₂N₅O⁺: 456.1819; found: 456.1820.



9-(furan-2-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5b):

Yield 60%; 214 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 191– 193 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.60 (s, 1H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.35 (t, *J* = 7.2 Hz, 1H), 6.84 (s, 1H), 6.65 (s, 1H), 3.92 (s, 3H), 1.96 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.3, 149.8, 149.6, 143.9, 143.2, 138.3, 135.1, 130.4, 129.0, 126.9, 122.3, 117.1, 112.3, 111.3, 107.3, 39.7, 13.1. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₀H₁₆N₅O₂⁺: 358.1299; found: 358.1296.



1,7-dimethyl-3-phenyl-9-(thiophen-2-yl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5c):

Yield 66%; 246 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 218–220 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.61 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 2H), 7.54-7.49 (m, 3H), 7.35 (t, *J* = 6.8 Hz, 1H), 7.23 (s, 1H), 7.16 (d, *J* = 3.2 Hz, 1H), 3.92 (s, 3H), 1.85 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.4, 149.8, 143.8, 138.5, 138.2, 138.1, 131.1, 129.7, 129.0, 127.8, 127.5, 126.8, 122.2, 117.4, 107.5, 39.6, 14.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₀H₁₆N₅OS⁺: 374.1070; found: 374.1069.



1,7-dimethyl-3-phenyl-9-(thiophen-3-yl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5d):

Yield 68%; 253 mg; white solid; column chromatography, silica gel (PE:EA, 8:1); mp 204–206 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.60-7.50 (m, 4H), 7.38 (d, *J* = 7.2 Hz, 1H), 7.33 (d, *J* = 4.8 Hz, 1H), 3.93 (s, 3H), 1.81 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.4, 150.0, 143.8, 140.0, 138.6, 138.3, 131.0, 129.1, 128.7, 127.1, 127.0, 126.4, 122.4, 117.5, 107.6, 39.6, 14.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₀H₁₆N₅OS⁺: 374.1070; found: 374.1070.



9-(2,5-dimethylfuran-3-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (5e):

Yield 67%; 357 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 226–228 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.14 (d, *J* = 8.0 Hz, 2H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.35 (t, *J* = 7.2 Hz, 1H), 6.18 (s, 1H), 3.92 (s, 3H), 2.37 (s, 3H), 2.13 (s, 3H), 2.08 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.3, 150.8, 150.0, 149.2, 143.4, 138.3, 138.1, 131.4, 128.9, 126.8, 122.2, 118.9, 117.4, 108.5, 107.5, 39.5, 15.5, 13.3, 12.3. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₂₀N₅O₂⁺: 386.1612; found: 386.1606.



9-(2,5-dimethylthiophen-3-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (5f):

Yield 73%; 292 mg; light yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 202–204 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.68 (s, 1H), 8.13 (d, *J* = 8.0 Hz, 2H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.2 Hz, 1H), 6.75 (s, 1H), 3.93 (s, 3H), 2.49 (s, 3H), 2.26 (s, 3H), 1.95 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 158.4, 152.3, 150.1, 143.9, 140.0, 138.3, 137.8, 137.3, 134.4, 131.5, 129.0, 127.4, 126.9, 122.4, 117.3, 107.5, 39.6, 15.1, 14.2, 13.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₂₀N₅OS⁺: 402.1383; found: 402.1381.



9-(benzofuran-2-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (5g):

Yield 66%; 268 mg; white solid; column chromatography, silica gel (PE:EA, 8:1); mp 210–212 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 8.12 (d, *J* = 7.6 Hz, 2H), 7.71 (d, *J* = 7.2 Hz, 1H), 7.56-7.50 (m, 3H), 7.43-7.33 (m, 3H), 7.23 (s, 1H), 3.96 (s, 3H), 1.86 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.4, 154.8, 152.3, 151.5, 149.9, 143.8, 138.2, 135.0, 130.2, 129.1, 128.1, 127.0, 125.8, 123.7, 122.4, 121.9, 117.2, 111.8, 107.6, 107.3, 39.9, 13.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₁₈N₅O₂⁺: 408.1455; found: 408.1443.



9-(benzo[b]thiophen-2-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (5h):

Yield 62%; 262 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 192–194 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 8.12 (d, *J* = 7.2 Hz, 2H), 7.92 (s, 1H), 7.80 (s, 1H), 7.53 (t, *J* = 6.8 Hz, 2H), 7.46-7.40 (m, 3H), 7.36 (t, *J* = 6.8 Hz, 1H), 3.95 (s, 3H), 1.88 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.4, 149.9, 143.7, 140.0, 139.2, 138.4, 138.2, 130.6, 129.1, 127.0, 126.4, 125.6, 125.0, 124.2, 122.4, 122.3, 117.5, 107.5, 39.8, 15.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₁₈N₅OS⁺: 424.1227; found: 424.1225.



9-(1H-indol-3-yl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5i):

Yield 59%; 239 mg; yellow solid; column chromatography, silica gel (PE:EA, 3:1); mp 272–274 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.75 (s, 1H), 8.87 (s, 1H), 7.80 (d, *J* = 7.6 Hz, 2H), 7.56 (t, *J* = 7.2 Hz, 2H), 7.50-7.43 (d, *J* = 8.4 Hz, 4H), 7.30 (t, *J* = 7.6 Hz, 1H), 7.16 (t, *J* = 7.2 Hz, 1H), 4.05 (s, 3H), 1.56 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.3, 151.6, 150.9, 144.9, 141.5, 136.3, 135.5, 133.2, 129.5, 128.9, 126.6, 125.2, 124.3, 123.7, 121.6, 119.0, 117.9, 113.4, 111.9, 108.0, 40.6, 14.8. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₁₉N₆O⁺: 407.1615; found: 407.1617.



1,7-dimethyl-3-phenyl-9-(quinolin-3-yl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5j):

Yield 52%; 217 mg; light yellow solid; column chromatography, silica gel (PE:EA, 4:1); mp 235–237 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.70 (s, 1H), 9.14 (s, 1H), 8.37 (s, 1H), 8.24 (d, *J* = 8.4 Hz, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.90 (d, *J* = 8.0 Hz, 1H), 7.85 (t, *J* = 7.6 Hz, 1H), 7.67 (t, *J* = 7.6 Hz, 1H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.2 Hz, 1H), 3.98 (s, 3H), 1.47 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.3, 150.1, 150.0, 147.9, 142.7, 141.1, 138.2, 136.2, 131.2, 130.8, 130.3, 129.5, 129.1, 128.1, 127.8, 127.3, 127.0, 122.3, 117.6, 107.2, 39.8, 16.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₅H₁₉N₆O⁺: 419.1615; found: 419.1613.



(*E*)-1,3,7-trimethyl-9-styryl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5k):

Yield 65%; 215 mg; light yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 174–176 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.54 (s, 1H), 7.59 (d, *J* = 7.6 Hz, 2H), 7.48 (d, *J* = 16.0 Hz, 1H), 7.45-7.38 (m, 3H), 7.36 (t, *J* = 6.0 Hz, 1H), 4.18 (s, 3H), 3.94 (s, 3H), 2.76 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 152.5, 149.7, 140.9, 140.8, 135.8, 134.1, 130.8, 128.9, 127.1, 124.0, 116.5, 105.5, 39.8, 34.1, 18.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₉H₁₈N₅O⁺: 332.1506; found: 332.1505.



(*E*)-1,7-dimethyl-3-phenyl-9-styryl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5l):

Yield 56%; 220 mg; yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 206–208 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.54 (s, 1H), 8.12 (d, *J* = 7.8 Hz, 2H), 7.57 (d, *J* = 7.3 Hz, 2H), 7.50 (t, *J* = 7.6 Hz, 2H), 7.44-7.34 (m, 6H), 3.91 (s, 3H), 2.78 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.1, 150.0, 142.4, 140.5, 138.3, 135.7, 134.0, 130.6, 129.0, 128.9, 127.1, 126.9, 124.0, 122.2, 117.0, 107.2, 39.7, 19.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₂₀N₅O⁺: 394.1662; found: 394.1664.



(*E*)-9-(4-(*tert*-butyl)styryl)-1,3,7-trimethyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5m):

Yield 67%; 259 mg; light yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 194–196 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.50 (s, 1H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.44 (d, *J* = 8.0 Hz, 2H), 7.40-7.34 (m, 2H), 4.16 (s, 3H), 3.92 (s, 3H), 2.77 (s, 3H), 1.36 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 152.4, 152.2, 149.6, 140.9, 140.8, 133.8, 132.9, 130.7, 126.9, 125.8, 122.9, 116.4, 105.4, 39.7, 34.7, 34.1, 31.2, 19.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₆N₅O⁺: 388.2132; found: 388.2129.



(*E*)-9-(4-chlorostyryl)-1,3,7-trimethyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (5n):

Yield 60%; 219 mg; light yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 200–202 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.55 (s, 1H), 7.51 (d, *J* = 7.6 Hz, 2H), 7.46 (d, *J* = 16.0 Hz, 1H), 7.41 (d, *J* = 7.6 Hz, 2H), 7.34 (d, *J* = 16.0 Hz, 1H), 4.18 (s, 3H), 3.94 (s, 3H), 2.75 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 152.6, 149.7, 140.8, 140.5, 134.7, 134.3, 132.7, 130.7, 129.2, 128.2, 124.7, 116.5, 105.4, 39.8, 34.1, 18.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₉H₁₇N₅OCl⁺: 366.1116; found: 366.1117.



(*E*)-1,3,7-trimethyl-9-(2-(naphthalen-1-yl)vinyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (50):

Yield 63%; 240 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 231–233 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 8.25 (t, *J* = 12.8 Hz, 2H), 7.88 (t, *J* = 7.6 Hz, 2H), 7.83 (d, *J* = 7.2 Hz, 1H), 7.61-7.50 (m, 4H), 4.17 (s, 3H), 3.99 (s, 3H), 2.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 152.5, 149.6, 140.9, 140.8, 133.7, 133.1, 131.3, 130.8, 130.6, 129.3, 128.7, 126.54, 126.47, 126.0, 125.5, 123.7, 123.3, 116.5, 105.5, 39.9, 34.1, 19.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₀N₅O⁺: 382.1662; found: 382.1662.



(*E*)-9-(2-(furan-2-yl)vinyl)-1,3,7-trimethyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5p):

Yield 58%; 186 mg; yellow solid; column chromatography, silica gel (PE:EA, 5:1); mp 195–197 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.56 (s, 1H), 7.51-7.47 (m, 2H), 7.27 (d, *J* = 3.2 Hz, 1H), 6.53 (d, *J* = 3.2 Hz, 1H), 6.49 (dd, *J* = 3.2 Hz, 2.0 Hz, 1H), 4.19 (s, 3H), 3.94 (s, 3H), 2.87 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 152.7, 152.3, 149.7, 143.5, 141.3, 140.3, 131.0, 122.0, 120.8, 116.6, 112.0, 111.5, 105.6, 39.8, 34.1, 19.1. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₇H₁₆N₅O₂⁺: 322.1299; found: 322.1299.



1,3,7-trimethyl-9-((1E,3E)-4-phenylbuta-1,3-dien-1-yl)-3,7-dihydro-6H-pyrazolo[4',3': 5,6]pyrido[3,4-d]pyridazin-6-one (5q):

Yield 64%; 228 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 224–226 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.52 (s, 1H), 7.48 (d, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.6 Hz, 2H), 7.31-7.22 (m, 2H), 7.06 (d, *J* = 15.2 Hz, 1H), 7.03-6.97 (m, 1H), 6.86 (d, *J* = 15.6 Hz, 1H), 4.18 (s, 3H), 3.93 (s, 3H), 2.84 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 152.5, 149.6, 140.8, 140.5, 136.8, 136.5, 134.1, 130.8, 128.7, 128.3, 127.33, 127.26, 126.7, 116.5, 105.5, 39.8, 34.1, 19.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₁H₂₀N₅O⁺: 358.1662; found: 358.1661.



1-cyclopropyl-3,7-dimethyl-9-((1E,3E)-4-phenylbuta-1,3-dien-1-yl)-3,7-dihydro-6Hpyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5r):

Yield 61%; 233 mg; yellow solid; column chromatography, silica gel (PE:EA, 7:1); mp 201–203 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.55 (s, 1H), 7.64 (d, *J* = 15.2 Hz, 1H), 7.45 (d, *J* = 7.6 Hz, 2H), 7.38-7.34 (m, 3H), 7.32-7.28 (m, 1H), 6.98 (dd, *J* = 15.6 Hz, 10.8 Hz, 1H), 6.85 (d, *J* = 15.6 Hz, 1H), 4.16 (s, 3H), 3.95 (s, 3H), 2.42-2.36 (m, 1H), 1.32-1.28 (m, 2H), 1.18-1.13 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 152.6, 149.6, 145.6, 140.5, 136.7, 136.4, 133.3, 130.9, 128.8, 128.3, 127.7, 127.4, 126.6, 116.5, 105.8, 39.9, 34.2, 13.3, 9.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₂N₅O⁺: 384.1819; found: 384.1820.



1,7-dimethyl-3,9-di-p-tolyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5s):

Yield 79%; 312 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 240–242 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.67 (s, 1H), 7.95 (d, *J* = 8.0 Hz, 2H), 7.45 (d, *J* = 7.6 Hz, 2H), 7.33 (d, *J* = 7.6 Hz, 4H), 3.93 (s, 3H), 2.47 (s, 3H), 2.42 (s, 3H), 1.62 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 152.3, 150.0, 144.4, 143.5, 139.7, 136.9, 135.9, 135.4, 130.8, 129.7, 129.6, 129.2, 122.5, 117.7, 107.5, 39.6, 21.4, 21.1, 15.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₂₂N₅O⁺: 396.1819; found: 396.1821.



3-(4-methoxyphenyl)-1,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (5t):

Yield 73%; 300 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 201–203 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 7.93 (d, *J* = 8.0 Hz, 2H), 7.44 (d, *J* = 7.2 Hz, 2H), 7.38-7.28 (m, 2H), 7.01 (d, *J* = 8.0 Hz, 2H), 3.91 (s, 3H), 3.84 (s, 3H), 2.46 (s, 3H), 1.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 151.9, 149.8, 144.3, 143.1, 139.5, 135.3, 131.4, 130.6, 129.6, 129.0, 123.8, 117.4, 114.0, 107.1, 55.4, 39.4, 21.3, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₂₂N₅O₂⁺: 412.1768; found: 412.1770.



3-(4-fluorophenyl)-1,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (5u):

Yield 69%; 275 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 216–218 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.13-8.07 (m, 2H), 7.44 (d, *J* = 7.6 Hz, 2H), 7.34 (d, *J* = 7.6 Hz, 2H), 7.19 (t, *J* = 8.4 Hz, 2H), 3.92 (s, 3H), 2.47 (s, 3H), 1.61 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.0 (d, *J* = 245.0 Hz, ¹*J*_{CF}), 158.3, 152.1, 150.0, 144.2, 143.7, 139.7, 135.2, 134.5 (d, *J* = 3.0 Hz, ⁴*J*_{CF}), 130.7, 129.7, 129.1, 123.8 (d, *J* = 8.0 Hz, ³*J*_{CF}), 117.7, 115.8 (d, *J* = 23.0 Hz, ²*J*_{CF}), 107.6, 39.5, 21.3, 15.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -114.91. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₉N₅OF⁺: 400.1568; found: 400.1568.



3-(4-chlorophenyl)-1,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (5v):

Yield 71%; 295 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 219–221 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 8.15 (d, *J* = 8.4 Hz, 2H), 7.45 (t, *J* = 8.0 Hz, 4H), 7.34 (d, *J* = 7.6 Hz, 2H), 3.93 (s, 3H), 2.47 (s, 3H), 1.61 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.3, 150.1, 144.3, 144.1, 139.8, 137.0, 135.3, 132.1, 130.7, 129.7, 129.10, 129.07, 123.0, 117.8, 108.0, 39.6, 21.4, 15.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₉N₅OCl⁺: 416.1273; found: 416.1271.



3-(4-bromophenyl)-1,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (5w):

Yield 66%; 303 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 215–217 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.09 (d, *J* = 8.0 Hz, 2H), 7.60 (d, *J* = 8.0 Hz, 2H), 7.43 (d, *J* = 7.6 Hz, 2H), 7.33 (d, *J* = 7.6 Hz, 2H), 3.93 (s, 3H), 2.47 (s, 3H), 1.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.3, 150.1, 144.2, 144.1, 139.8, 137.5, 135.3, 132.0, 130.7, 129.7, 129.1, 123.2, 119.9, 117.8, 108.0, 39.6, 21.4, 15.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₉N₅OBr⁺: 460.0767; found: 460.0766.



3-(2,6-dimethylphenyl)-1,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (5x):

Yield 78%; 319 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 147– 149 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 7.51 (d, *J* = 7.6 Hz, 2H), 7.38 (d, *J* = 7.6 Hz, 2H), 7.31 (q, *J* = 7.6 Hz, 1H), 7.21 (d, *J* = 7.6 Hz, 2H), 3.94 (s, 3H), 2.48 (s, 3H), 1.92 (s, 6H), 1.67 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 153.2, 150.5, 144.4, 143.7, 139.6, 136.7, 135.4, 135.3, 131.0, 129.6, 129.1, 128.3, 117.4, 105.6, 39.5, 21.3, 17.5, 15.3. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₅H₂₄N₅O⁺: 410.1975; found: 410.1973.


3-(2,4-dichlorophenyl)-1,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (5y):

Yield 72%; 324 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 210–212 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 7.62 (s, 1H), 7.51-7.41 (m, 4H), 7.36 (d, *J* = 7.2 Hz, 2H), 3.93 (s, 3H), 2.48 (s, 3H), 1.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 153.6, 150.6, 144.7, 144.2, 139.7, 135.8, 135.1, 133.8, 133.0, 131.0, 130.4, 130.3, 129.7, 129.1, 127.8, 117.8, 106.7, 39.5, 21.3, 15.3. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₈N₅OCl₂⁺: 450.0883; found: 450.0882.



1,7-dimethyl-3-(3-nitrophenyl)-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (5z):

Yield 68%; 289 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 226–228 °C. ¹H NMR (400 MHz, CDCl₃, CF₃COOD) δ 9.61 (s, 1H), 9.08 (s, 1H), 8.68 (d, *J* = 8.0 Hz, 1H), 8.10 (d, *J* = 8.0 Hz, 1H), 7.64 (t, *J* = 8.4 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 3.95 (s, 3H), 2.49 (s, 3H), 1.61 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, CF₃COOD) δ 159.0, 152.5, 150.3, 148.4, 145.9, 145.3, 140.4, 139.0, 134.5, 131.0, 129.95, 129.86, 129.1, 127.1, 121.0, 117.8, 116.5, 108.4, 40.2, 21.3, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₁₉N₆O₃⁺: 427.1513; found: 427.1515.



1,7-dimethyl-3-(pyridin-2-yl)-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6a):

Yield 56%; 213 mg; white solid; column chromatography, silica gel (PE:EA, 3:1); mp 226–228 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.75 (s, 1H), 8.70 (d, *J* = 3.6 Hz, 1H), 8.37 (d, *J* = 8.4 Hz, 1H), 7.94 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 7.6 Hz, 2H), 7.36-7.30 (m, 3H), 3.94 (s, 3H), 2.47 (s, 3H), 1.68 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.7, 150.5, 150.3, 149.1, 145.1,

144.2, 139.8, 138.3, 135.2, 130.7, 129.7, 129.0, 122.1, 118.1, 117.1, 108.5, 39.5, 21.3, 15.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₉N₆O⁺: 383.1615; found: 383.1613.0



1,3,7-trimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6b):

Yield 83%; 264 mg; white solid; column chromatography, silica gel (PE:EA, 7:1); mp 188–190 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.60 (s, 1H), 7.42 (d, *J* = 7.6 Hz, 2H), 7.32 (d, *J* = 7.6 Hz, 2H), 4.16 (s, 3H), 3.93 (s, 3H), 2.46 (s, 3H), 1.54 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 152.7, 149.5, 144.4, 142.1, 139.5, 135.3, 130.7, 129.6, 129.1, 116.9, 105.8, 39.5, 34.0, 21.3, 15.1. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₈H₁₈N₅O⁺: 320.1506; found: 320.1508.



1,3,7-trimethyl-9-(thiophen-3-yl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6c):

Yield 76%; 236 mg; white solid; column chromatography, silica gel (PE:EA, 6:1); mp 195–197 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.53 (s, 1H), 7.56 (s, 1H), 7.51-7.48 (s, 1H), 7.30 (d, *J* = 4.4 Hz, 1H), 4.14 (s, 3H), 3.91 (s, 3H), 1.72 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 152.7, 149.3, 142.1, 139.9, 138.6, 130.9, 128.7, 126.8, 126.3, 116.6, 105.5, 39.5, 33.9, 14.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₅H₁₄N₅OS⁺: 312.0914; found: 312.0913.



1,7-dimethyl-9-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6d):

Yield 69%; 200 mg; yellow solid; column chromatography, silica gel (PE:EA, 3:1); mp 261–263 °C. ¹H NMR (400 MHz, DMSO- d_6) δ 14.08 (s, 1H), 9.32 (s, 1H), 7.55-7.50 (m, 5H), 3.76

(s, 3H), 1.33 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 157.7, 154.5, 148.6, 143.8, 142.2, 138.1, 130.2, 129.5, 129.3, 128.8, 116.4, 104.5, 39.1, 14.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₆H₁₄N₅O⁺: 292.1193; found: 292.1191.



3-(tert-butyl)-1,7-dimethyl-9-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6e):

Yield 76%; 263 mg; white solid; column chromatography, silica gel (PE:EA, 10:1); mp 256–258 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.60 (s, 1H), 7.56-7.48 (m, 5H), 3.93 (s, 3H), 1.84 (s, 9H), 1.50 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 152.6, 147.6, 144.5, 139.9, 138.4, 130.2, 129.3, 129.2, 128.9, 116.4, 106.9, 60.5, 39.4, 29.1, 15.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₀H₂₂N₅O⁺: 348.1819; found: 348.1817.



3-cyclohexyl-1,7-dimethyl-9-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6f):

Yield 79%; 294 mg; white solid; column chromatography, silica gel (PE:EA, 10:1); mp 220–222 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 7.56-7.50 (m, 5H), 5.04-4.96 (m, 1H), 3.92 (s, 3H), 2.12-1.98 (m, 4H), 1.96-1.90 (m, 2H), 1.77 (d, *J* = 12.8 Hz, 1H), 1.60-1.49 (m, 2H), 1.52 (s, 3H), 1.39-1.28 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 151.7, 148.8, 144.3, 141.6, 138.2, 130.5, 129.3, 129.2, 128.8, 116.9, 105.6, 55.8, 39.4, 32.1, 25.4, 25.1, 14.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₂₄N₅O⁺: 374.1975; found: 374.1976.



3-benzyl-1,7-dimethyl-9-phenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6g):

Yield 76%; 289 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 175–177 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 7.53-5.49 (m, 5H), 7.36 (d, *J* = 7.2 Hz, 2H), 7.29-7.23 (m, 3H), 5.70 (s, 2H), 3.92 (s, 3H), 1.50 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 152.6, 149.7, 144.3, 142.6, 138.1, 136.3, 130.6, 129.4, 129.2, 128.9, 128.5, 128.0, 127.8, 117.2, 105.9, 50.7, 39.5, 15.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₃H₂₀N₅O⁺: 382.1662; found: 382.1662.



ethyl 2-(1,7-dimethyl-6-oxo-9-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-3-yl)acetate (6h):

Yield 62%; 233 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 173– 175 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 7.57-7.50 (m, 5H), 5.32 (s, 2H), 4.24 (q, *J* = 7.2 Hz, 2H), 3.94 (s, 3H), 1.52 (s, 3H), 1.28 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 158.6, 153.3, 150.0, 144.3, 143.4, 138.1, 130.8, 129.6, 129.3, 129.0, 117.5, 106.2, 61.8, 48.2, 39.6, 15.0, 14.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₀H₂₀N₅O₃⁺: 378.1561; found: 378.1559.



1-cyclopropyl-3,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6i):

Yield 73%; 251 mg; white solid; column chromatography, silica gel (PE:EA, 10:1); mp 210–212 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 7.47 (d, *J* = 7.6 Hz, 2H), 7.29 (d, *J* = 7.6 Hz, 2H), 4.12 (s, 3H), 3.94 (s, 3H), 2.42 (s, 3H), 0.74-0.69 (m, 2H), 0.57-0.50 (m, 1H), 0.39-0.33 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 152.4, 149.3, 147.2, 144.4, 139.0, 135.4, 130.4, 129.5, 128.6, 117.0, 106.0, 39.5, 34.0, 21.2, 10.2, 10.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₀H₂₀N₅O⁺: 346.1662; found: 346.1662.



3,7-dimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6j):

Yield 82%; 250 mg; white solid; column chromatography, silica gel (PE:EA, 8:1); mp 183–185 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 7.6 Hz, 2H), 7.18 (s, 1H), 4.21 (s, 3H), 3.96 (s, 3H), 2.51 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.8, 151.3, 149.6, 144.8, 140.0, 133.0, 132.7, 130.0, 129.6, 128.8, 116.7, 107.2, 39.8, 34.4, 21.4. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₇H₁₆N₅O⁺: 306.1349; found: 306.1346.



3-ethyl-7-methyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6k):

Yield 77%; 245 mg; yellow solid; column chromatography, silica gel (PE:EA, 8:1); mp 177– 179 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 7.46 (d, *J* = 7.6 Hz, 2H), 7.39 (d, *J* = 7.6 Hz, 2H), 7.17 (s, 1H), 4.65 (q, *J* = 7.2 Hz, 2H), 3.96 (s, 3H), 2.50 (s, 3H), 1.54 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.9, 150.8, 149.5, 144.9, 140.0, 133.1, 132.8, 130.1, 129.7, 128.9, 116.8, 107.4, 42.6, 39.8, 21.4, 14.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₈H₁₈N₅O⁺: 320.1506; found: 320.1504.



7-methyl-3-phenyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6l):

Yield 72%; 264 mg; yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 177– 179 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.71 (s, 1H), 8.15 (d, *J* = 8.0 Hz, 2H), 7.55 (t, *J* = 7.6 Hz, 2H), 7.49 (d, *J* = 7.6 Hz, 2H), 7.44-7.36 (m, 3H), 7.32 (s, 1H), 3.97 (s, 3H), 2.52 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.6, 151.1, 150.2, 144.7, 140.2, 138.5, 134.5, 132.6, 130.1, 129.8, 129.2, 128.9, 127.2, 122.2, 117.3, 109.0, 39.9, 21.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₈N₅O⁺: 368.1506; found: 368.1504.



1-(tert-butyl)-7-methyl-3-phenyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido [3,4-d]pyridazin-6-one (6m):

Yield 54%; 228 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 266–268 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.59 (s, 1H), 8.21 (d, *J* = 8.0 Hz, 2H), 7.55 (t, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.6 Hz, 1H), 7.30 (d, *J* = 7.6 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 3.92 (s, 3H), 2.37 (s, 3H), 0.99 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 154.6, 152.4, 149.0, 145.4, 139.6, 138.6, 135.7, 130.3, 129.7, 129.0, 128.9, 126.8, 122.4, 118.8, 107.3, 39.1, 35.1, 29.9, 21.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₆H₂₆N₅O⁺: 424.2132; found: 424.2128.



7-methyl-1,3-diphenyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6n):

Yield 65%; 287 mg; light yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 225–227 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.74 (s, 1H), 8.22 (d, *J* = 8.0 Hz, 2H), 7.54 (t, *J* = 7.6 Hz, 2H), 7.37 (t, *J* = 7.2 Hz, 1H), 7.15 (t, *J* = 8.0 Hz, 4H), 7.10-7.05 (m, 1H), 7.02 (t, *J* = 7.2 Hz, 2H), 6.69 (d, *J* = 7.6 Hz, 2H), 3.95 (s, 3H), 2.11 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.5, 150.4, 147.4, 144.1, 138.8, 138.3, 134.2, 133.8, 130.0, 129.2, 129.0, 128.6,

128.2, 127.4, 127.3, 127.2, 122.6, 118.8, 106.2, 39.6, 20.9. HRMS (ESI-TOF): $m/z \ [M+H]^+$ calcd for $C_{28}H_{22}N_5O^+$: 444.1819; found: 444.1818.



1,7-dimethyl-9-(p-tolyl)isoxazolo[4',5':5,6]pyrido[3,4-d]pyridazin-6(7H)-one (6o):

Yield 61%; 186 mg; white solid; column chromatography, silica gel (PE:EA, 8:1); mp 217–219 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.74 (s, 1H), 7.43 (d, *J* = 7.2 Hz, 2H), 7.38 (d, *J* = 7.2 Hz, 2H), 3.93 (s, 3H), 2.49 (s, 3H), 1.55 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 157.6, 155.9, 152.9, 143.4, 140.3, 134.3, 132.1, 129.9, 129.2, 119.5, 105.1, 39.6, 21.3, 12.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₇H₁₅N₄O₂⁺: 307.1190; found: 307.1191.



1,7-dimethyl-9-(p-tolyl)isoxazolo[4',5':5,6]pyrido[3,4-d]pyridazin-6(7H)-one (6p):

Yield 63%; 213 mg; yellow solid; column chromatography, silica gel (PE:EA, 7:1); mp 193–195 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.75 (s, 1H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.41 (d, *J* = 8.0 Hz, 2H), 3.94 (s, 3H), 2.57 (s, 3H), 1.63 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 157.7, 155.8, 153.1, 142.9, 141.9, 133.4, 132.0, 129.6, 126.4, 119.6, 105.1, 39.8, 15.3, 13.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₇H₁₅N₄O₂S⁺: 339.0910; found: 339.0909.



2,7-dimethyl-9-phenyl-2,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6q):

Yield 32%; 93 mg; white solid; column chromatography, silica gel (PE:EA, 1:1); mp 279–281 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.68 (s, 1H), 7.65-7.55 (m, 5H), 6.95 (s, 1H), 4.11 (s, 3H), 3.96 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 159.4, 158.9, 150.8, 144.5, 135.8, 130.5, 129.9, 129.0, 128.9, 125.7, 117.2, 106.3, 41.2, 40.0. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₆H₁₄N₅O⁺: 292.1193; found: 292.1192.



1,2,7-trimethyl-9-phenyl-2,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6r):

Yield 57%; 174 mg; white solid; column chromatography, silica gel (PE:EA, 1:1); mp 292–294 °C. ¹H NMR (400 MHz, CDCl₃ + CF₃CO₂D) δ 9.67 (s, 1H), 7.66-7.50 (m, 5H), 4.10 (s, 3H), 3.99 (s, 3H). 1.63 (s, 3H). ¹³C NMR (100 MHz, CDCl₃ + CF₃CO₂D) δ 158.3, 153.9, 149.2, 144.2, 137.6, 137.4, 133.6, 130.1, 129.5, 128.9, 117.7, 106.4, 40.3, 38.8, 12.1. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₇H₁₆N₅O⁺: 306.1349; found: 306.1350.



3,7,9-trimethyl-1-phenylpyrimido[5',4':5,6]pyrido[3,4-d]pyridazine-4,8,10(3H,7H,9H)-trione (6s):

Yield 72%; 251 mg; yellow solid; column chromatography, silica gel (DCM:EA, 6:1); mp 267–269 °C. ¹H NMR (400 MHz, CDCl₃ + CF₃CO₂D) δ 8.06 (s, 1H), 7.47-7.36 (m, 5H), 3.67 (s, 3H), 3.55 (s, 3H), 3.53 (s, 3H).¹³C NMR (100 MHz, CDCl₃ + CF₃CO₂D) δ 167.0, 161.2, 159.7, 158.9, 148.2, 143.2, 135.7, 131.2, 129.7, 124.3, 102.6, 99.3, 97.0, 33.2, 31.9, 29.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₈H₁₆N₅O₃⁺: 350.1248; found: 350.1246.



3,7,9-trimethyl-1-(4-(methylthio)phenyl)pyrimido[5',4':5,6]pyrido[3,4-d]pyridazine-4,8,10(3H,7H,9H)-trione (6t):

Yield 75%; 296 mg; yellow solid; column chromatography, silica gel (DCM:EA, 5:1); mp 244-246 °C. ¹H NMR (400 MHz, CDCl₃ + CF₃CO₂D) δ 8.08 (s, 1H), 7.28 (d, *J* = 8.4 Hz, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 3.67 (s, 3H), 3.55 (s, 3H), 3.52 (s, 3H), 2.46 (s, 3H).¹³C NMR (100 MHz, CDCl₃ + CF₃CO₂D) δ 166.9, 161.2, 159.6, 159.0, 148.2, 143.3, 143.2, 131.8, 126.5, 124.8, 102.7, 99.1, 97.0, 33.2, 31.9, 29.9, 14.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₉H₁₈N₅O₃S⁺: 396.1125; found: 396.1124.



1-methyl-3,9-diphenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6u):

Yield 66%; 332 mg; yellow solid; column chromatography, silica gel (DCM:EA, 3:1); mp 292–294 °C. ¹H NMR (400 MHz, DMSO- d_6) δ 13.40 (s, 1H), 9.47 (s, 1H), 8.09 (d, J = 8.0 Hz, 2H), 7.62-7.54 (m, 7H), 7.41 (t, J = 7.6 Hz, 1H), 1.46 (s, 3H). ¹³C NMR (100 MHz, DMSO- d_6) δ 158.5, 152.2, 149.2, 144.2, 143.3, 138.4, 138.0, 131.1, 129.4, 129.3, 129.2, 128.9, 126.9, 122.1, 118.0, 107.7, 14.8. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₁H₁₆N₅O⁺: 354.1349; found: 354.1341.



7-benzyl-1-methyl-3,9-diphenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-6-one (6v):

Yield 73%; 323 mg; light yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 204–206 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 8.10 (d, *J* = 7.6 Hz, 2H), 7.60-7.49 (m, 9H), 7.37-7.32 (m, 3H), 7.30 (d, *J* = 7.2 Hz, 1H), 5.49 (s, 2H), 1.57 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.0, 152.4, 150.3, 144.5, 143.7, 138.3, 138.2, 136.2, 130.6, 129.6, 129.3, 129.09, 129.07, 128.8, 128.6, 127.9, 127.0, 122.4, 118.1, 107.7, 55.1, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₈H₂₂N₅O⁺: 444.1819; found: 444.1818.



1-methyl-3,7,9-triphenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6w):

Yield 65%; 278 mg; yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 191– 193 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.75 (s, 1H), 8.14 (d, *J* = 8.0 Hz, 2H), 7.75 (d, *J* = 8.0 Hz, 2H), 7.64-7.59 (m, 2H), 7.56-7.47 (m, 7H), 7.42-7.33 (m, 2H), 1.62 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 157.9, 152.6, 150.5, 144.9, 143.8, 141.1, 138.3, 138.1, 130.5, 129.7, 129.3, 129.1, 128.7, 128.0, 127.0, 125.3, 122.3, 118.6, 107.8, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₇H₂₀N₅O⁺: 430.1662; found: 430.1663.



1,3-dimethyl-7,9-diphenyl-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6x):

Yield 71%; 260 mg; white solid; column chromatography, silica gel (PE:EA, 6:1); mp 206–208 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 7.73 (d, *J* = 8.0 Hz, 2H), 7.61-7.56 (m, 2H), 7.54-7.46 (m, 5H), 7.39 (t, *J* = 7.6 Hz, 1H), 4.18 (s, 3H), 1.53 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 153.0, 150.0, 145.1, 142.3, 141.1, 138.1, 130.5, 129.6, 129.3, 129.0, 128.7, 128.0, 125.4, 117.9, 106.0, 34.1, 14.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₂H₁₈N₅O⁺: 368.1506; found: 368.1505.



1,5,7-trimethyl-3-phenyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (6y):

Yield 59%; 233 mg; yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 201–203 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.0 Hz, 2H), 7.51 (t, *J* = 8.0 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.34-7.29 (m, 3H), 3.90 (s, 3H), 3.27 (s, 3H), 2.45 (s, 3H), 1.56 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.0, 158.9, 151.1, 144.1, 143.6, 139.5, 138.6, 135.8, 132.4, 129.7, 128.9, 126.4, 121.8, 117.0, 107.4, 40.1, 28.1, 21.4, 15.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₄H₂₂N₅O⁺: 396.1819; found: 396.1817.



1,3,5,7-tetramethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin -6-one (6z):

Yield 61%; 262 mg; white solid; column chromatography, silica gel (PE:EA, 10:1); mp 206–208 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 7.6 Hz, 2H), 8.04-7.95 (m, 2H), 7.91 (d, *J* = 6.8 Hz, 1H), 7.84 (d, *J* = 6.8 Hz, 1H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.58-7.48 (m, 4H), 7.32 (t, *J* = 6.8 Hz, 1H), 3.93 (s, 3H), 3.29 (s, 3H), 1.36 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 162.1, 158.9, 151.1, 143.9, 143.4, 138.6, 135.8, 133.3, 133.1, 132.3, 128.9, 128.5, 128.3, 127.8, 127.1, 126.8, 126.4, 126.3, 121.8, 117.1, 107.3, 40.1, 28.1, 15.8. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₇H₂₂N₅O⁺: 432.1819; found: 432.1819.



1,3,5,7-tetramethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin -6-one (7a):

Yield 65%; 216 mg; white solid; column chromatography, silica gel (PE:EA, 7:1); mp 198–200 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 7.6 Hz, 2H), 7.28 (d, *J* = 7.2 Hz, 2H), 4.10 (s, 3H), 3.89 (s, 3H), 3.23 (s, 3H), 2.44 (s, 3H), 1.47 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 161.4, 159.1, 151.4, 144.2, 142.0, 139.3, 135.8, 132.5, 129.6, 129.0, 116.3, 105.3, 40.0, 33.6, 27.9, 21.3, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₁₉H₂₀N₅O⁺: 334.1662; found: 334.1661.



1-cyclopropyl-3,5,7-trimethyl-9-(p-tolyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-one (7b):

Yield 60%; 215 mg; white solid; column chromatography, silica gel (PE:EA, 10:1); mp 232–234 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, *J* = 7.2 Hz, 2H), 7.24 (d, *J* = 7.2 Hz, 2H), 4.07 (s, 3H), 3.90 (s, 3H), 3.23 (s, 3H), 2.40 (s, 3H), 0.67-0.62 (m, 2H), 0.53-0.46 (m, 1H), 0.35-0.30 (m, 2H).¹³C NMR (100 MHz, CDCl₃) δ 161.3, 159.1, 151.2, 147.0, 144.2, 138.9, 135.9, 132.2, 129.6, 128.6, 116.4, 105.7, 40.0, 33.7, 27.8, 21.2, 10.2, 9.5. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₁H₂₂N₅O⁺: 360.1819; found: 360.1818.





Yield 67%; 367 mg; yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 239–241 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.21 (d, *J* = 8.0 Hz, 2H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.66 (dd, *J* = 16.4 Hz, 7.6 Hz, 2H), 7.52 (t, *J* = 8.0 Hz, 2H), 7.35 (t, *J* = 7.2 Hz, 1H), 4.99 (td, J = 10.8 Hz, 4.0 Hz, 1H), 3.93 (s, 3H), 2.19 (d, J = 11.6 Hz, 1H), 2.03-1.95 (m, 1H), 1.75 (d, J = 11.6 Hz, 2H), 1.61 (s, 3H), 1.60-1.51 (m, 2H), 1.17 (q, *J* = 12.0 Hz, 2H), 0.95 (t, *J* = 6.4 Hz, 7H), 0.83 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 158.2, 152.2, 149.9, 143.2, 143.1, 142.1, 138.2, 131.6, 130.1, 130.0, 129.24, 129.16, 129.0, 126.8, 122.1, 117.5, 107.3, 75.3, 47.1, 40.8, 39.6, 34.1, 31.3, 26.5, 23.6, 21.9, 20.6, 16.5, 15.8. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₃H₃₆N₅O₃⁺: 550.2813; found: 550.2810.



(2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-9-yl)benzoate (7d):

Yield 60%; 328 mg; light yellow solid; column chromatography, silica gel (PE:EA, 6:1); mp 286–288 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.67 (s, 1H), 8.22 (d, *J* = 8.0 Hz, 2H), 8.13 (d, *J* =

8.0 Hz, 2H), 7.68 (d, J = 6.4 Hz, 2H), 7.53 (t, J = 8.0 Hz, 2H), 7.36 (t, J = 7.6 Hz, 1H), 5.18 (d, J = 9.2 Hz, 1H), 3.94 (s, 3H), 2.56-2.48 (m, 1H), 2.22-2.07 (m, 1H), 1.90-1.81 (m, 1H), 1.80-1.76 (m, 1H), 1.63 (s, 3H), 1.48-1.41 (m, 1H), 1.38-1.31 (m, 1H), 1.18 (dd, J = 14.0 Hz, 3.2 Hz, 1H), 1.00 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 166.0, 158.3, 152.3, 150.0, 143.23, 143.15, 142.3, 138.3, 131.8, 130.1, 129.3, 129.1, 127.0, 122.3, 117.7, 107.4, 81.0, 49.1, 47.9, 44.9, 39.7, 36.8, 28.0, 27.4, 19.7, 18.9, 15.9, 13.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₃H₃₄N₅O₃⁺: 548.2656; found: 548.2658.



N-((*1s*,*3R*,*5r*,*7S*)-adamantan-1-yl)-4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-9-yl)benzamide (7e):

Yield 57%; 310 mg; light yellow solid; column chromatography, silica gel (PE:EA, 4:1); mp 298–300 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.64 (s, 1H), 8.10 (d, *J* = 7.6 Hz, 2H), 7.89 (d, *J* = 7.6 Hz, 2H), 7.61 (d, *J* = 7.6 Hz, 2H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.2 Hz, 1H), 6.00 (s, 1H), 3.92 (s, 3H), 2.22-2.12 (m, 9H), 1.78-1.70 (m, 6H), 1.60 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 158.2, 152.2, 149.9, 143.24, 143.15, 140.6, 138.2, 136.8, 130.1, 129.3, 129.0, 127.4, 126.9, 122.2, 117.5, 107.3, 41.5, 39.6, 36.2, 29.4, 15.9. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₃H₃₃N₆O₂⁺: 545.2662; found: 545.2656.



4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d] pyridazin-9-yl)phenyl 4-(*N*,*N*-dipropylsulfamoyl)benzoate (7f):

Yield 65%; 422 mg; yellow solid; column chromatography, silica gel (PE:EA, 4:1); mp 209–211 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.70 (s, 1H), 8.37 (d, *J* = 7.6 Hz, 2H), 8.14 (d, *J* = 7.6 Hz, 2H), 7.98 (d, *J* = 8.0 Hz, 2H), 7.68 (d, *J* = 7.6 Hz, 2H), 7.54 (t, *J* = 7.2 Hz, 2H), 7.46-7.35 (m, 3H), 3.96 (s, 3H), 3.15 (t, *J* = 7.6 Hz, 4H), 1.75 (s, 3H), 1.58 (q, *J* = 7.6 Hz, 4H), 0.90 (t, *J*

= 7.2 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 163.5, 158.3, 152.3, 151.5, 149.9, 145.0, 143.4, 143.2, 138.2, 136.1, 132.3, 130.8, 130.6, 130.4, 129.0, 127.1, 126.9, 122.3, 122.2, 117.6, 107.5, 49.8, 39.6, 21.8, 15.5, 11.1. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₅H₃₅N₆O₅S⁺: 651.2384; found: 651.2384.



(4S)-*N*-(4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-9-yl)phenyl)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxamide (7g):

Yield 69%; 387 mg; yellow solid; column chromatography, silica gel (PE:EA, 4:1); mp 260–262 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.50 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.91 (d, *J* = 7.6 Hz, 1H), 7.76 (d, *J* = 7.6 Hz, 1H), 7.57 (d, *J* = 8.0 Hz, 2H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.35 (d, *J* = 7.2 Hz, 1H), 3.92 (s, 3H), 2.67-2.61 (m, 1H), 2.09-1.99 (m, 2H), 1.80-0.73 (m, 1H), 1.70 (s, 3H), 1.19 (s, 3H), 1.16 (s, 3H), 1.03 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 177.6, 165.4, 158.2, 152.2, 149.8, 143.4, 143.3, 138.2, 138.0, 134.5, 130.3, 129.95, 129.90, 128.9, 126.7, 122.0, 120.1, 120.0, 117.5, 107.5, 92.2, 55.3, 54.3, 39.5, 30.3, 28.9, 16.6, 16.4, 15.7, 9.6. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₂H₃₁N₆O₄⁺: 563.2401; found: 563.2403.



(R)-N-(4-(1,7-dimethyl-6-oxo-3-phenyl-6,7-dihydro-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-9-yl)phenyl)-2-(4-isobutylphenyl)propanamide (7h):

Yield 74%; 421 mg; light yellow solid; column chromatography, silica gel (PE:EA, 4:1); mp 206–208 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.10 (d, *J* = 8.0 Hz, 2H), 7.84 (s, 1H), 7.73 (d, *J* = 7.6 Hz, 1H), 7.64 (d, *J* = 7.6 Hz, 1H), 7.52-7.44 (m, 4H), 7.34 (t, *J* = 7.2 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 2H), 7.14 (d, *J* = 7.6 Hz, 2H), 3.88 (s, 3H), 3.77 (q, J = 6.4 Hz, 1H), 2.45

(d, J = 7.2 Hz, 2H), 1.88-1.81 (m, 1H), 1.66 (s, 3H), 1.60 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 6.4 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 172.9, 158.3, 152.3, 149.9, 143.8, 143.5, 141.0, 139.5, 138.2, 137.9, 133.6, 130.5, 129.7, 129.0, 127.3, 126.8, 122.2, 119.6, 117.6, 107.6, 47.6, 44.9, 39.5, 30.0, 22.3, 18.6, 15.8. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₅H₃₅N₆O₂⁺: 571.2816; found: 571.2815.



1,7-dimethyl-3-phenyl-9-(4-(phenylethynyl)phenyl)-3,7-dihydro-6H-pyrazolo[4',3':5,6] pyrido[3,4-d]pyridazin-6-one (8):

Yield 86%; 120 mg; yellow solid; column chromatography, silica gel (PE:EA, 12:1); mp 165–167 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 2H), 7.68 (d, *J* = 8.0 Hz, 2H), 7.58-7.48 (m, 6H), 7.37-7.32 (m, 4H), 3.93 (s, 3H), 1.69 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 158.2, 152.2, 149.9, 143.4, 143.3, 138.2, 137.7, 132.1, 131.5, 130.2, 129.2, 129.0, 128.5, 128.3, 126.8, 124.6, 122.6, 122.2, 117.6, 107.5, 91.1, 88.5, 39.6, 15.7. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₀H₂₂N₅O⁺: 468.1819; found: 468.1819.



9-(4-(di-p-tolylphosphoryl)phenyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-6H-pyrazolo [4',3':5,6]pyrido[3,4-d]pyridazin-6-one (9):

Yield 84%; 149 mg; yellow solid; column chromatography, silica gel (PE:EA, 2:1); mp 258–260 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.10 (d, *J* = 7.6 Hz, 2H), 7.92-7.81 (m, 2H), 7.68 (d, *J* = 6.8 Hz, 2H), 7.64-7.55 (m, 4H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.34-7.28 (m, 5H), 3.92 (s, 3H), 2.42 (s, 6H), 1.60 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 158.1, 152.1, 149.9, 142.9, 142.6 (d, *J* = 3.0 Hz, ⁴*J*_{CP}), 141.1 (d, *J* = 3.0 Hz, ⁴*J*_{CP}), 138.1, 134.9 (d, *J* = 101.0 Hz, ¹*J*_{CP}), 132.6 (d, *J* = 10.0 Hz, ³*J*_{CP}), 131.9 (d, *J* = 10.0 Hz, ³*J*_{CP}), 130.0, 129.2 (d, *J* = 12.0 Hz, ²*J*_{CP}), 129.1 (d, *J* = 12.0 Hz, ²*J*_{CP}), 128.9, 128.2, 126.9, 122.1, 117.5, 107.2, 39.6, 21.5, 15.5. ³¹P NMR (162

MHz, CDCl₃) δ 28.53. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₃₆H₃₁N₅O₂P⁺: 596.2210; found: 596.2208.



6-chloro-1-methyl-3,9-diphenyl-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine (10):

Yield 91%; 67 mg; light yellow solid; column chromatography, silica gel (PE:EA, 10:1); mp 286-288 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.10 (d, *J* = 8.0 Hz, 2H), 7.73-7.66 (m, 2H), 7.62-7.50 (m, 5H), 7.39 (t, *J* = 7.6 Hz, 1H), 1.67 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 158.3, 152.9, 151.1, 149.3, 144.2, 138.6, 138.0, 130.1, 129.8, 129.13, 129.07, 127.4, 126.8, 122.5, 117.3, 105.7, 15.2. HRMS (ESI-TOF): m/z [M+H]⁺ calcd for C₂₁H₁₅N₅Cl⁺: 372.1010; found: 372.1009.

7. Crystallographic data and molecular structure of 4e and 7b



Supplementary Figure 10. Molecular structure of 4e with 50% probability ellipsoids Crystal Data for Compound **4e**: CCDC 2344553 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic.

Sample preparation: In a 10 mL glass bottle, 8 mg of pure **4e** was completely dissolved in the mixed solvent of 3 mL EtOAc, 1 mL EtOH, 1 mL CHCl₃; 1 mL MeCN and then 2 mL of n-hexane was added slowly. After a week of solvent evaporation, some colorless transparent crystals were obtained. The crystals were mounted on a glass fiber for diffraction experiments. Intensity data were collected on a Bruker SMART APEX CCD diffractometer with Mo K α radiation (0.71073 Å) at room temperature.

Datablock: y

| Bond precision: | C-C = 0.0030 A | Wavelength=0.71073 | |
|--------------------------------------|-----------------------------|--------------------|-----------------------------------|
| Cell: | a=7.563(3) | b=11.483(4) | c=13.531(4) |
| Temperature: | aipna=76.835(5) 296 K | Deta=/8.800(5) | gamma=//.22/(5) |
| | Calculated | Repo | rted |
| Volume | 1103.2(7) | 1103 | .2(6) |
| Space group | P -1 | P -1 | |
| Hall group | -P 1 | -P 1 | |
| Moiety formula | C23 H19 N5 O2 [+ | solvent] C23 H | H19 N5 O2 |
| Sum formula | C23 H19 N5 O2 [+ | solvent] C23 H | H19 N5 O2 |
| Mr | 397.43 | 397.4 | 13 |
| Dx,g cm-3 | 1.196 | 1.190 | 5 |
| Z | 2 | 2 | |
| Mu (mm-1) | 0.080 | 0.080 |) |
| F000 | 416.0 | 416.0 |) |
| F000' | 416.16 | | |
| h,k,lmax | 9,13,16 | 9,13, | .16 |
| Nref | 4106 | 4059 | |
| Tmin, Tmax | 0.984,0.992 | 0.630 | 5,0.746 |
| Tmin' | 0.984 | | |
| Correction metho AbsCorr = MULTI- | od= # Reported T L -SCAN | imits: Tmin=0.63 | 36 Tmax=0.746 |
| Data completene: | ss= 0.989 | Theta(max)= 2 | 25.499 |
| R(reflections)= | 0.0532(3134) | | wR2(reflections)= 0.1748(4059) |
| S = 1.026 | Npar= 2 | 74 | 0.17.10(1000) |



Supplementary Figure 11. Molecular structure of 7b with 50% probability ellipsoids Crystal Data for Compound **7b**: CCDC 2344669 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic.

Sample preparation: In a 10 mL glass bottle, 8 mg of pure **7b** was completely dissolved in the mixed solvent of 3 mL EtOAc, 1 mL EtOH, 1 mL CHCl₃; 1 mL MeCN and then 2 mL of n-hexane was added slowly. After a week of solvent evaporation, some colorless transparent crystals were obtained. The crystals were mounted on a glass fiber for diffraction experiments. Intensity data were collected on a Bruker SMART APEX CCD diffractometer with Mo K α radiation (0.71073 Å) at room temperature.

Datablock: mo_220107d_0m

| Bond precision: | C-C = 0.0046 A | Wavelength=0.71073 | | |
|--------------------------------------|----------------------------|-------------------------|-----------------------------------|--|
| Cell: | a=7.260(4) alpha=90 | b=21.655(12) beta=90 | c=23.676(13) gamma=90 | |
| Temperature: | 296 K | | | |
| | Calculated | Reported | | |
| Volume | 3722(4) | 3722(4) | | |
| Space group | РЬСа | Pbca | | |
| Hall group | -P 2ac 2ab | -P 2ac 2ab | | |
| Moiety formula | C21 H21 N5 O | C21 H21 N5 O | | |
| Sum formula | C21 H21 N5 O | C21 H21 N5 O | | |
| Mr | 359.43 | 359.43 | | |
| Dx,g cm-3 | 1.283 | 1.283 | 1.283 | |
| Z | 8 | 8 | | |
| Mu (mm-1) | 0.083 | 0.083 | 0.083 | |
| F000 | 1520.0 | 1520.0 | | |
| F000′ | 1520.52 | | | |
| h,k,lmax | 8,26,28 | 8,26,28 | | |
| Nref | 3464 | 3448 | | |
| Tmin,Tmax | 0.990,0.992 | 0.395,0.7 | 46 | |
| Tmin' | 0.984 | | | |
| Correction metho AbsCorr = MULTI- | d= # Reported T Li SCAN | mits: Tmin=0.395 Tm | nax=0.746 | |
| Data completenes | s= 0.995 | Theta(max) = 25.50 | 0 | |
| R(reflections) = | 0.0796(2371) | 60 | wR2(reflections)= 0.2259(3448) | |
| 1.070 | Mpar- 20 | | | |

8. ¹H, ¹³C ¹⁹F and ³¹P NMR spectra of compounds 4a





90 80 70 60 50 40 30

20 10 0












































0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200































5f











80 70 60

40 30

20 10



















S102











S107

90 80 70 60 50 40 30 20 10







5w




























90

80 70

60 50

40 30

20 10

0

190

170

150

130

110





















6n















-11.56 ---0.00 ---0.00 ---0.00 ---0.00



6s CDCl₃, CF₃CO₂D 400 MHz





-10.53 − -10.53 - -10.53 - -10.53 - -0.08 - -2.46 - -2.46 - -2.46 - -0.00 - -



6t CDCl₃, CF₃CO₂D 400 MHz











w

S134

 







---0.00 -1.36 8.22 8.21 8.21 8.21 8.21 7.398 7.7.99 8.21 7.298 7.7.99 7. -3.29 -3.93 ,CH₃ 6z H₃C **CDCl**₃ 400 MHz CH--2:00 -2:05 -1:05 -1:02 -1:02 00 3.01 8 ή ć .0 8.0 7.0 6.0 5.0 4.0 2.0 0.0 10.0 9.0 3.0 1.0 -162.09 -162.09 -158.86 -145.107 -138.40 -138.577 -133.29 -133.29 -133.29 -133.29 -133.29 -128.38 -128.38 -126.83 -126.83 -107.34 -107.34-40.15 77.32 777.00 76.68 -15.75 -- 28.14 ,CH₃ 6z H₃C CDCl₃ 100 MHz CH3 10 190 170 130 110 150 90 80 70 60 50 40 30 20 10 0

6z





7a



















7e



7f



80 70 60

20 10




S145



8





-1.69

-39.57

-15.71

-0.00

-3.93













S147





References

(1) Seeberger, Peter H. ; Pereira, Claney L.; Khan, Naeem; Xiao, Guozhi; Diago-Navarro, Elizabeth. *Angew. Chem. Int. Ed.* 56, 13973-13978 (2017).

(2) Rochon, Kristina; Proteau-Gagne, Arnaud; Bourassa, Philippe; Nadon, Jean-Francois; Cote, Jerome. *ACS Chemical Neuroscience*. *4*, 1204-1216 (2013).

(3) Maura Marinozzi, Andrea Carotti, Emanuele Sansone, Antonio Macchiarulo, Emiliano Rosatelli, Roccaldo Sardella. *Bioorg. Med. Chem.* **20**, 3429-3445 (2012).

(4) Bhaskar Deka, Pranjal K. Baruah, Mohit L. Deb. Org. Biomol. Chem. 16, 7806-7810 (2018).

(5) Lei Pan, Feng Jin, Rui Fu, Ke Gao, Shaofang Zhou, Xiaoguang Bao. *Eur. J. Org. Chem.*2020, 2956-2961 (2020).

- (6) Preparation method of 1-aryl-5-hydroxypyrazole. China, CN104059020 A 2014-09-24.
- (7) Method and device for preparing hydroxypyrazole compounds *via* continuous reaction.China, CN109320457 A 2019-02-12.
- (8) Domaradzki, M. E.; Long, Y.; She, Z.; Liu, X.; Zhang, G.; Chen, Y. J. Org. Chem. 80, 11360-11368 (2015).

(9). Kailu Zheng, Hannan Yang, Fan Ni, Zhanxiang Chen, Shaolong Gong, Zhenghong Lu and Chuluo Yang. *Adv. Optical Mater.* **7**, 1900727 (2019).

(10). You Zhou, Shuang-Gui Lei, Li-Sheng Wang, Jin-Tian Ma, Zhi-Cheng Yu, Yan-Dong Wu, and An-Xin Wu. *Org. Lett.* **25**, 3386-3390 (2023).